Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of ...

Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra ...

Due to the rapid evolution of the digital world, it’s more important than ever for LBM dealers stay atop the technology curve ...

Jules performs better than Gemini CLI despite using the same model, and more like Claude Code and OpenAI Codex.

Atea Pharmaceuticals, Inc. ( AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements November 13, 2025 10:00 AM EST Jordan Feld Anthony Martinez Nancy Reau Eric ...

In the Phase III results presented and published today, olezarsen demonstrated rapid, substantial and significant reductions in triglycerides by up to 72% on top of standard of care and reduced the ...

The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...

Heart failure with preserved ejection fraction, or HFpEF, is now the most common form of heart failure. Many people who ...

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. It announced today ...

HIGHLIGHTS: Koné project comprises 7 mineralised trends hosting 52 identified targets with mineralization confirmed at all 23 ...

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections ...